Genomic Vision has received a new patent for its “physical properties of telomeres” technique based on molecular combing.

BAGNEUX, France, June 16, 2022– (Business Wire) – Regulatory News:

Genomic Vision (FR0011799907 – GV, PEA-PME eligible) (Paris: GV)A biotechnology company that develops tools and services dedicated to the analysis and control of genome mutations has today announced the successful publication of a patent on “Physical Properties of Telomeres” (PCT).

The patent was granted in June 2022 by the United States Patent and Trademark Office (USPTO) and the World Intellectual Property Organization (WIPO). Through this patent, Genomic Vision Ownership is expanding its portfolio of innovations, adding a new dimension to molecular use. Comb technology for age-related diseases and the onset of certain cancers.

What is telomeres?

The telomeres are the protective regions located at the ends of each chromosome. Each time a cell divides, the telomeres become smaller. There comes a time when telomeres become so small that the cells no longer divide and die. In light of this phenomenon, the shortening or loss of telomeres has opened up a wide range of applications related to biological and age-related diseases that could lead to a breakthrough in medicine for the treatment of chronic diseases and contribute to longevity.

What are PCT patent applications?

Thanks to this invention, genomic vision technology can be used not only to detect the physical length of telomeres, but also to identify regions of the genome near or not in telomeres; It is associated with diseases or biomarkers for which telomere shortening or damage identification is crucial.

Using artificial intelligence (AI), PCT applications will automatically detect signals and create an internal database.

Based on the PCT patent, the overall strategy of Genomic Vision is to provide integrated bio-analytical tools in the following areas:

  • Age-related diseases;

  • Improvement of living conditions;

  • Study of telomere length on genome scale;

  • Biomarker detection for diseases associated with specific chromosomes;

  • Assist in early diagnosis of the disease.

In the third quarter of 2021, Genomic Vision has already launched its TeloSizer® service, an innovative tool for physically measuring the size and distribution of telomeres to establish a link between telomeres’ length and disease onset as well as their severity. . This new patent provides additional knowledge needed to determine how telomere length can serve, among other things, as a biomarker of drugs.

Dominic Remy-Renu, CEO of Genomic Vision, says: “We are proud to receive this patent, which enables us to make our technology more secure in a variety of applications. Intellectual property policy is an integral part of our development strategy and I would like to thank our IP team for this achievement.”

About genomic vision

Genomic Vision is a biotechnology company that develops products and services dedicated to genome mutation analysis (structural and functional) as well as quality and safety control of these mutations, especially in genome editing technology and organic production processes. Genomic Vision’s proprietary tools, based on DNA combing technology and artificial intelligence, provide powerful quantitative measurements required for reliable traits of DNA mutations in the genome. These tools are used to significantly monitor DNA replication in cancer cells, early detection of cancer, and genetic diagnosis. Located in Bagneux, in the Paris region, the company has about 30 employees. Genomic Vision is listed on the Euronext regulated market in Paris, compartment C (Euronext: GV-ISIN: FR0011799907).

www.genomicvision.com

Caution

This press release contains an implicit or explicit frontline statement regarding genomic vision and its activities. Genomic Vision believes that these far-sighted statements are based on reasonable assumptions. However, no guarantee can be made about the achievement of the forecasts published in these advance statements described in the “Reasons for Risk” section of the Universal Registration Document filed with the Autorite des Marches Financier, which is a matter of risk. AMF) has been updated by the amendment filed with the Autorité des Marchés Financiers (AMF) on May 20, 2022, under registration number D. 22-0293, dated April 14, 2022, D.22-0293- Under A01, the company website available here (www.genomicvision.com) and changes in economic conditions, financial markets and markets where there is a genomic vision. The far-sighted statements in this press release also do not consider genomic vision to be an unknown risk factor or genomic vision material to date. Realization of all or part of these risks may materially differ from the actual results, financial status, performance or achievement of Genomic Vision’s published results, financial status, performance or achievements.

This press release and the information contained in it shall not constitute an offer or invitation to sell or subscribe to any country, nor shall it be construed as an order request or an invitation to purchase or subscribe to Genomic Vision shares. Distribution of these press releases in certain countries may be a violation of effective legal provisions. The occupants of the press release must inform themselves of any local restrictions and comply with them.

See the source version at businesswire.com: https://www.businesswire.com/news/home/20220616005853/en/

Introduction

Genomic vision
Dominic Remy-Renu
Chairman of the Board of Directors
E.g. : +33 1 49 08 07 51
investors@genomicvision.com

Ulysses Communication
Press relations
Bruno Arabian
E.g. : +33 1 42 68 29 70
barabian@ulysse-communication.com

Newcap
Investor Relations
And strategic communication
E.g. : +33 1 44 71 94 94
gv@newcap.eu

Leave a Comment